News and Updates
QART Medical Featured in Jerusalem Post Article Showcasing Improvement in Pregnancy Rates
QART Medical is excited to share a recent Jerusalem Post article which featured QART Medical's advanced technology and improvement of IVF success rates. The piece highlights Professor Shaked’s groundbreaking work in advancing IVF technology, specifically through QART Medical’s pioneering use of quantitative phase microscopy to analyze sperm cells in a clinical setting. Said Professor Shaked, “The continued media coverage and recognition of QART's work underscores the transformative potential of our technology, and we look forward to further revolutionizing the IVF industry. We’re thrilled that sustained media attention is helping to spread the word about our work and the impact it will have on the future of IVF.”
To read the article on the Jerusalem Post website please Click Here.
QART Medical is an ISO13485 certified MedTech company addressing the global infertility epidemic. To do so, QART has developed the Q300™, a breakthrough solution to male infertility issues that provides a quantitative characterization of sperm cell morphology to facilitate informed clinical decision making when selecting cells for use in in-vitro fertilization (IVF). QART aims to improve current success rates of Intra-Cytoplasmic Sperm Injection (ICSI) by quantitatively characterizing the morphology and composition of individual sperm cells with 3D imaging. The Q300™ is registered with the US FDA, has received Israeli regulatory registration for commercial sales, and bears the CE (Conformité Européenne) Mark.
QART Medical Featured in Mirage News Article Showcasing Improvement in Pregnancy Rates
QART Medical is proud to share that its cofounder, Professor Natan Shaked, was recently featured in an article in Mirage News. The article highlights how QART Medical’s innovative approach to IVF, using quantitative phase microscopy to analyze sperm cells, a novel capability pioneered by Professor Shaked's lab, could change the landscape of fertility treatments.
Read moreQART Medical Featured in Israel21c Article Showcasing Improvement in Pregnancy Rates
QART Medical is proud to share that its cofounder, Professor Natan Shaked, was recently featured in an article in Israel21c. The article highlights how Professor Shaked is leading the charge in revolutionizing the IVF field, leveraging QART Medical’s cutting-edge quantitative phase microscopy technology to analyze sperm cells in new ways with deep clinical meaning.
Read moreQART Medical Featured in Medialine Article Showcasing Improvement in Pregnancy Rates
QART Medical is excited to announce that its cofounder, Professor Natan Shaked, was recently featured in an article in Medialine. The piece highlights Professor Shaked’s groundbreaking work in advancing IVF technology, with a focus on
QART Medical’s innovative use of quantitative phase microscopy to analyze sperm cells in a clinical setting.
To read the article on the Medialine website please Click Here.
Professor Natan Shaked, cofounder of QART Medical
QART Medical is an ISO13485 certified MedTech company addressing the global infertility epidemic. To do so, QART has developed the Q300™, a breakthrough solution to male infertility issues that provides a quantitative characterization of sperm cell morphology to facilitate informed clinical decision making when selecting cells for use in in-vitro fertilization (IVF). QART aims to improve current success rates of Intra-Cytoplasmic Sperm Injection (ICSI) by quantitatively characterizing the morphology and composition of individual sperm cells with 3D imaging. The Q300™ is registered with the US FDA, has received Israeli regulatory registration for commercial sales, and bears the CE (Conformité Européenne) Mark.
QART Medical and its cofounder, Natan Shaked, Featured in Haaretz Article Showcasing Improvement in Pregnancy Rates
QART Medical, its cofounder Professor Natan Shaked, and the Barzilay Medical Center IVF clinical team, Featured in Haaretz Article Showcasing Groundbreaking Technology
Read moreCompelling Interim Results from QART Medical’s Multi-center Clinical Outcome Study Presented at ESHRE 2024 Annual Meeting
QART Medical is excited to announce that the company's work was presented at the European Society Of Human Reproduction and Embryology (ESHRE) Annual Meeting 2024. This year’s ESHRE conference took place in Amsterdam from July 7-10. Dr. Bujana Sa`ar-Ris, MD, head of BMC’s (Barzilai medical center, Ashkelon, Israel) IVF unit and Dr. Yulia Michailov, PhD, manager of BMC’s IVF lab, presented QART Medical outcome study results.
The paper presented, titled “Preliminary Clinical Outcome Using the Q300™ Device in a Reproductive Laboratory Environment”, summarizes the first 24 cases that the BMC team conducted in their IVF unit, which was the pioneering site for this study.
This study is meant to assess the impact of using QART’s Q300™ system under routine IVF workflow. The data presented was based on a cutoff after 24 initial couples enrolled into the study, and shows an increase of 75% in chances of having a usable embryo for transfer on day 3, an increase of 35% in the chances of having a good blastocysts for transfer on day 5 and an increase of 100% in the chances of generating clinical pregnancy, following chemical pregnancy (i.e., positive beta hormone test).
Additional IVF units have since joined this multi-center study, and results from a larger and more diversified cohort of patients are due to be released in Q4 2024. The image below shows Dr Sa’ar-Ris (left) and Dr Michailov at ESHRE 2024 adjacent the e-poster presentation of the study results.
“This is an exciting point in time for male fertility and IVF specialists. QART’s product - Q300™ - is the first to allow IVF clinicians harness the power of highly-informative holographic imaging and advanced machine vision, to examine compliance of individual sperm cells with consensus WHO criteria for good human sperm morphology. This is achieved as part of the routine IVF workflow. We extend our deep gratitude to the Barzilai IVF team for their continued scientific and clinical pioneering collaboration” says Alon Shalev, CEO of QART Medical.
Professor Natan Tzvi Shaked,Qart Co-Founder and CSO, Invited to Speak at Aspire’s 2024 Conference in Manilla
QART Medical’s co-founder and chief scientific officer, was invited to speak at the 13th congress of the Asia Pacific Initiative on Reproduction’s (ASPIRE) in Manilla, Philippines. Prof Shaked, in his Academic role, is director of biomedical engineering at Tel-Aviv University.
Professor Shaked’s ASPIRE talk, titled "Sperm DNA Fragmentation Assay for Live Human Sperm During ICSI”, detailed the years of research output from the Biomedical OMNI (Optical Microscopy, Nanoscopy, and Interferometry) Group that he leads at Tel Aviv University that led to the spin out of QART Medical. Additionally, he explained the advanced research and development that he leads, to bring real time DNA fragmentation analysis, on a single-cell level, to its flagship product, the Q300™.
Following the talk and a Q&A session, Prof Shaked participated in a panel discussion, revolving around the importance of assessing DNA fragmentation in live, motile human sperm cells, to optimize IVF success rates.
ASPIRE, the Asia Pacific Initiative on Reproduction, was founded in 2001 by Bruno Lunenfeld and P C Wong, to improve knowledge and awareness of ART and infertility-related services, with the ultimate aim of improving the quality of patient care.
Dr Yulia Michailov presented interim clinical outcome results from QART MEDICAL’s multi-center clinical study
QART Medical is honored to have the company’s interim clinical results presented at the Israel Fertility Association’s 66th annual conference.
The poster, titled “Preliminary Clinical Outcome Using the Q300™ Device in a Reproductive Laboratory Environment”, was one of 19 featured posters at this year’s conference. The poster summarizes the preliminary interim results from QART’s on-going, multi-center clinical study at Barzilai Medical Center in Ashkelon, Israel.
The study is meant to provide an understanding of the early clinical impact of the Q300™ in the IVF laboratory. The initial data suggests favorable outcomes, with further research necessary to identify the patient subgroups that can derive the greatest benefit from this system. The preliminary results focus on 14 couples attempting to achieve pregnancy. A copy of the poster can be found here: QART Medical Poster
The Israel Fertility Association (AYALA) conference, held yearly in Tel Aviv, brings together the country’s leading fertility experts with a focus on new technologies, techniques, and procedures.
QART Medical, a Male Fertility Company, Discloses Recent Financing
March 5th, Raanana, Israel – Chartered-Opus investment managers was joined by Eastern Epic Capitals, a Singapore based venture capital fund which focuses on frontier technologies to create value and make the world a better place, led an extension of a Series A round of financing, as well as additional angel investment.
“We are happy to have Eastern EPIC Capitals join the long-standing commitment of QART investors at this very exciting inflection point in QART. Our flagship product, Q300™, is the first and only highly informative companion for male fertility treatments. Q300™ is now FDA, CE-Mark and AMAR (Israeli MoH) cleared for marketing, and we’ve started a multi-center clinical study to look at real-life aspects of its use, such as improvement in the clinical indicators of clinical success”, said Alon Shalev, CEO and Co-founder of QART Medical.
Dr Mitch Rosen, MD, an expert in reproductive endocrinology and fertility and the director of the UCSF Fertility Preservation Program, where QART’s Q300 system is now being evaluated “As counter-intuitive as it may sound, only sperm matters. I mean, oocytes are vital, but scarce. In each retrieval we typically withdraw half a dozen, up to a dozen of them… therefore we’re going to try and create embryos from all of them. With sperm cells, you could have hundreds of millions of those with likely unequal developmental capacity. They are tiny, transparent, they’re in motion, and they rotate and go in and out of focus. QART’s system and technology may revolutionize the selection process to capture the ideal sperm cell to enhance the chances of successful fertilization and pregnancy”
About QART Medical QART Medical is an ISO13485 certified MedTech company addressing the global infertility epidemic. To do so, QART has developed the Q300™, a breakthrough solution to male infertility issues that provides a quantitative characterization of sperm cell morphology to facilitate informed clinical decision making when selecting cells for use in in-vitro fertilization (IVF). QART aims to improve current success rates of Intra-Cytoplasmic Sperm Injection (ICSI) by quantitatively characterizing the morphology and composition of individual sperm cells with 3D imaging. The Q300™ is registered with the US FDA, has received Israeli regulatory registration for commercial sales, and bears the CE (Conformité Européenne) Mark.